Celyad Oncology SA (EBR:CYAD)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.3860
+0.0360 (10.29%)
Jun 27, 2025, 5:25 PM CET
40.88%
Market Cap 15.99M
Revenue (ttm) 186.00K
Net Income (ttm) -5.82M
Shares Out 41.43M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,848
Average Volume 32,025
Open 0.3560
Previous Close 0.3500
Day's Range 0.3500 - 0.3900
52-Week Range 0.2120 - 1.2200
Beta 1.07
RSI 43.82
Earnings Date Sep 25, 2025

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 19
Stock Exchange Euronext Brussels
Ticker Symbol CYAD
Full Company Profile

Financial Performance

In 2024, Celyad Oncology's revenue was 186,000, an increase of 82.35% compared to the previous year's 102,000. Losses were -5.82 million, -31.06% less than in 2023.

Financial Statements

News

There is no news available yet.